Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandutinib + Bevacizumab in Recurrent High-Grade Gliomas
NCT00667394Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2008
- Primary completion
- Jul 2011
- Countries
- 1
- Sponsor
- National Cancer Institute
- Modality
- Orthosteric Ligands
- Drugs
- tandutinib
- Conditions
- glioma
01
Overview
Phase 2, open-label trial of tandutinib in glioma (2 cohorts), sponsored by National Cancer Institute. Primary endpoint: Progression-free Survival at 6 Months. Started Apr 2008; status: completed.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
GBM Cohort
Patients with Glioblastoma Multiforme
AG Cohort
Patients with Anaplastic Glioma
03
Endpoints
Primary
Progression-free Survival at 6 Months
Secondary
Number of Participants With Adverse Events
Beyond the preview
Go deeper on NCT00667394.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00667394.